Abstract
Duration of exposure to select DNA-damaging therapy and the risk of secondary myelodysplastic syndrome and acute myeloid leukemia in patients with ovarian or breast cancer in a real-world setting in the United States
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
